Metabolic Innovations

Breakthrough medications for type 2 diabetes and obesity. Stay informed about the latest GLP-1 receptor agonists, their clinical trial results, FDA approval timelines, and insurance coverage outlook.

🔬 Research Pipeline

Investigational GLP-1 medications in clinical development from Eli Lilly, Novo Nordisk, and Amgen. Track FDA approval timelines, trial results, and insurance coverage outlook for breakthrough obesity treatments.

Amgen

Maritide
Amgen

GLP-1 agonist + GIP antagonist. Monthly dosing (every 4 weeks). Phase 3 MARITIME program. 20% weight loss.

Learn more →

Eli Lilly

Orforglipron
Eli Lilly

Oral GLP-1 - no fasting requirement. FDA-approved as Foundayo (April 1, 2026). 11.2% weight loss.

Learn more →
Retatrutide
Eli Lilly

Triple-action injectable (GIP+GLP-1+Glucagon). Phase 3 TRIUMPH program. Record 24.2% weight loss.

Learn more →
Mazdutide
Eli Lilly

Dual GLP-1/Glucagon agonist. Phase 2 US development. 14.8% weight loss in trials.

Learn more →

Novo Nordisk

CagriSema
Novo Nordisk

Combination therapy (Cagrilintide + Semaglutide). Phase 3 REDEFINE program. Record 25.3% weight loss.

Learn more →
Oral Semaglutide (Obesity)
Novo Nordisk

Oral semaglutide for obesity. 25 mg approved as the Wegovy pill (December 22, 2025); 50 mg studied in OASIS 1.

Learn more →

Roche

CT-388
Roche (Genentech)

Signal-biased dual GLP-1/GIP agonist. Phase 2 ongoing. 18.8% weight loss at 24 weeks. Phase 3 H1 2026.

Learn more →

Viking Therapeutics

VK2735
Viking Therapeutics

Dual GLP-1/GIP agonist. Phase 3 VANQUISH program. 14.7% weight loss at 13 weeks. Oral formulation also in development.

Learn more →

Boehringer Ingelheim

Survodutide
Boehringer Ingelheim

Dual GLP-1/Glucagon agonist. Phase 3 SYNCHRONIZE program. 18.7% weight loss. Also targeting MASH with 62% resolution.

Learn more →

What We Cover

For each medication, we provide comprehensive information to help you make informed decisions:

  • Clinical Trial Results: Detailed analysis of Phase 2 and Phase 3 trial data, including efficacy, safety, and responder rates
  • FDA Approval Status: Real-time tracking of regulatory milestones, submission dates, and approval timelines
  • Side Effects & Safety: Comprehensive safety profiles with management strategies for common adverse events
  • Insurance Coverage: Coverage predictions, formulary tier placement, and prior authorization requirements
  • Head-to-Head Comparisons: Evidence-based comparisons between similar medications to guide treatment decisions
Clinical Trials — Actively Recruiting
Find trials currently enrolling patients. Free access to next-generation GLP-1 medications before FDA approval.
→

Last updated October 6, 2026

Disclaimer

The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.

While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.